FREE Shippingto US, AU, UK and EU on all orders over $149
/

Cinnarizine 25 mg (50 tablets)

$2.80

cf442652d1ce

Description

The trade name
Cinnarizine

the International unlicensed

name Cinnarizine Dosage Form

of the Tablet Structure One Tablet contains
active agent – cinnarizine of 25.00 mg,
excipients: lactoses monohydrate, starch wheat, silicon dioxide colloidal (aerosil 200), Povidone-K25 (K 25 polyvinylpirrolidone), talc, magnesium stearate.

The description
of the Tablet of white or almost white color, round, with a biconvex surface.

Pharmacotherapeutic group
Drugs for treatment of diseases of nervous system others. Means for elimination of dizziness. Cinnarizine.
The ATX N07CA02 code

the Pharmacological

Pharmacokinetics Drug properties is soaked up in a stomach and intestines. The maximum concentration in blood plasma after intake in 1-3 hours. Communication of cinnarizine with proteins of plasma makes 91%. It is completely metabolized in a liver (by means of dealkylation). Elimination half-life is equal to 4 hours. It is removed in the form of metabolites: 1/3 – kidneys and 2/3 – with stool – intestines.
The pharmacodynamics
Cinnarizine inhibits reduction of cells of smooth muscles of vessels by means of blocking of calcium channels. In addition, cinnarizine is a direct antagonist of calcium and reduces sokratitelny activity of vasoactive substances, such as Norepinephrinum and serotonin, blocking a receptor – the managed calcium channels. Blockade of inflow of calcium to cells is tkaneselektivny and leads to reduction of vasoconstriction without influence on arterial blood pressure and heart rate. Cinnarizine can improve in addition insufficient microcirculation, enhancing deformability of erythrocytes and reducing viscosity of blood. At its reception the resistance of cells to a hypoxia increases.
Drug reduces stimulation of a vestibular system therefore the nystagmus and other autonomous symptoms of vegetative disorders disappears. Drug interferes with emergence or blocks symptoms of a bad attack of dizziness.

Indications
– prevention and treatment of the vestibular disturbances arising in Menyer’s disease such as dizziness, sonitus, nausea, vomiting
– prevention and treatment of a motion desease.

A route of administration and doses
Inside, after a meal.
Vestibular disturbances
Adult, elderly and teenagers are more senior than 12 years: 3 times a day on 1 tablet.
Children from 6 to 12 years: a half of an adult dose is recommended.
The recommended doses should not be exceeded.
A motion desease
Adult, elderly and teenagers is more senior than 12 years: 1 tablet in 2 hours prior to a travel, further on 1/2 tablets each 8 hours during the way.
Children from 6 to 12 years: a half of an adult dose is recommended.

Side effects
Often
– drowsiness, the dispeptic phenomena (usually are passing and can be prevented at gradual achievement of an optimum dose)
Seldom
– dryness in a mouth, increase in body weight
– a headache
– the increased perspiration
– allergic reactions
Very seldom
– red flat deprive, volchanochnopodobny reactions
– the only case of cholestatic jaundice
– at patients of senile age at prolonged use of drug are possible extrapyramidal disorders, a depression. In such cases it is necessary to interrupt a therapy course.

Contraindications
– hypersensitivity to drug components
– children’s age up to 6 years.

Medicinal interactions
the Accompanying alcohol intake and use of the means oppressing activity of the central nervous system or tricyclic antidepressants can strengthen sedative action of any of the listed medicines or the drug Cinnarizine.
Because of antihistaminic action when conducting skin allergy tests Cinnarizine can cover positive reaction to factors of skin reactivity. For prevention of it it is not necessary to take the drug in 4 days prior to conducting skin tests.

The discomfort in epigastric area Can cause special instructions, use after a meal reduces irritation of a mucous membrane of a stomach.
Patients with Parkinson’s disease should appoint only when advantages of its appointment exceed possible risk of aggravation of symptoms.
With care it is applied in the presence of the following diseases: profound hypotonia, diseases of a liver and kidneys.
Tablets contain lactoses monohydrate, in this regard patients with rare hereditary diseases, such as intolerance of a galactose, a lactose intolerance of Lapp or glucose galactose absorption disturbance should not take the drug.
Cinnarizine can cause drowsiness, especially in an initiation of treatment therefore it is necessary to show care at the accompanying alcohol intake or reception of the means oppressing activity of the central nervous system.
Pregnancy and the period of a lactation
Drug has to be used during pregnancy only if the therapeutic advantage for mother justifies potential risk for a fruit.
There are no data on drug discharge in female breast milk therefore the women accepting Cinnarizine have to refuse breastfeeding.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
drowsiness development, especially in an initiation of treatment is possible therefore it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Overdose
Symptoms: vomiting, drowsiness, tremor, hypotonia, coma.
Treatment: specific antidote does not exist, drug withdrawal, gastric lavage, administration of activated carbon, performing symptomatic therapy is recommended.

The form of release and packing
On 50 tablets place in blister strip packaging from a film of polyvinylchloride and aluminum foil.
On 1 planimetric packing together with the instruction for medical use in the state and Russian languages place in a pack from cardboard.

Storage conditions
In the dry, protected from light place, at a temperature not above 25 °C.
To store out of children’s reach.

3 years
not to use a period of storage after an expiration date.

Prescription status
According to the prescription

Additional information

Ingredient

Reviews

There are no reviews yet.

Be the first to review “Cinnarizine 25 mg (50 tablets)”

Your email address will not be published.